RxDoctor Payments Data

Narendra Patel, MD

Ophthalmology · Greensboro, NCNPI 1467657866

Payments from drug & device makers

$3,220in general payments, 2019–2025

Across 102 payments — averaging $31.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$873
  • Apellis Pharmaceuticals, Inc.$338
  • AbbVie$296
  • Amgen$247
  • Eyepoint US, Inc.$233
  • Alimera Sciences, Inc.$208
  • plus $1K from 14 others

What the payments were for

  • Speaking & faculty fees$211%
  • Food & beverage$3,16098%
  • Gifts$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,220 in reported general payments places this provider in the 65th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,196,793
Medicare patients
402
Services billed
14,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Alphagan PBrimonidine Tartrate37$7,630
Prednisolone Acetate124$6,350
Ofloxacin352$4,158
LumiganBimatoprost13$3,145
Brimonidine Tartrate47$1,436
Ketorolac Tromethamine64$1,020
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha58$758
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat49$719
Dorzolamide Hcl29$612
Timolol Maleate94$520
Latanoprost67$417
ErythromycinErythromycin Base21$193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P, Lumigan$296$10,77650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →